-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 20, Hengrui Medicine issued an announcement stating that its subsidiary Suzhou Shengdia Biomedical Co.
SHR-1314 injection is a recombinant humanized monoclonal antibody that targets human IL-17A independently developed by the company and is intended to treat autoimmune diseases related to the IL-17 pathway.
According to the announcement, up to now, the accumulated research and development expenses of SHR-1314 related research and development projects have been about 211.